Who is Monica Bertagnolli, Bidens pick to lead NIH? CEO Pablo Cagnoni will step down Nov. 15, along with the biotech's chief financial officer and top lawyer. More recently, some companies have opted to close entirely. Lamentamos pelo inconveniente. New biotechs continue to emerge despite a challenging market environment that has persisted in 2023, forcing venture firms to build their drug startups more cautiously. Dannielle Appelhans, to Become President and Chief Executive Officer, Pablo J. Cagnoni, M.D., Appointed Chair of the Board of Directors, CAMBRIDGE, Mass., November 2, 2022 (GLOBE NEWSWIRE) Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics for the treatment of cancer and autoimmune diseases, today announced that it has initiated a process to explore a range of strategic alternatives to maximize shareholder value and plans to engage an investment bank to act as a strategic advisor for this process. Founded in 2013, Rubius Therapeutics is headquartered in Cambridge, Massachusetts. Even if its a quite capable market brawler like AbbVie. Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Follow PBN for the latest news, insider access and more. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook. Rubius stock traded lower by around 9% in morning trading at 15 cents apiece, half their value in November when the company put itself up for sale and well off highs above $27 apiece in 2021. Accordingly, we urge extreme caution with respect to existing and future investments in our securities. Subscribe to BioPharma Dive for top news, trends & analysis, The free newsletter covering the top industry headlines, Evinatures Co-Founder Nir Salomon Hits the Road for 2023s Lecture Tour in USAs Leading Medi, Ymmunobio Appoints New Chief Operating Officer, Excelra Acquires BISC Global, Creating an International Bioinformatics Powerhouse with an Indu, Ymmunobio to Present at the Annual Meeting of the Association for Cancer Immunotherapy (CIMT), By signing up to receive our newsletter, you agree to our, Big pharmas looming threat: a patent cliff of tectonic magnitude, FDA approves new ALS medicine in precedent-setting decision, Alnylams early Alzheimers results encourage, but company discloses new hurdle, FDA clears Pfizers pneumococcal vaccine for infants and children, Novartis trims 10% of drug pipeline in research cutback, The latest developments on the gene therapy frontier.
info@cappelectric.com
713.681.7339